University of Pittsburgh Health Sciences eLearning Environment Internet-based Studies in Education and Research
INTRODUCTION
ABIM and DOB Data Collection
9/21/2021 - Medical Grand Rounds: COVID-19 Update
QUIZ
EVALUATION
CERTIFICATE
Credit Hours: CME 1.00
Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.
COVID-19 Update: Staying safe, vaccinations, and the end(?)
Presented by: Elise Martin, MD, MS & Graham Snyder, MD, MS
COVID-19 Monoclonal Antibodies: Modern Twist on an Old Tool
Presented by: Ryan Bariola, MD
Upon completion of this activity, participants should be able to:
- Review the current epidemiology of the COVID-19 pandemic
- Describe how infection prevention measures, vaccination, and therapeutics (including monoclonal antibody) improve the well-being of patients and healthcare workers related to the SARS-CoV-2 virus.
- Enumerate and quantify the benefits of COVID-19 vaccination, including during spread of the Delta variant.
- Review the role of COVID-19 neutralizing monoclonal antibodies in the treatment of COVID-19 infection
- Describe the appropriate patients who would benefit from COVID-19 monoclonal antibodies
Suggested additional reading:
- Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462. doi:10.1016/S0140-6736(21)01358-1
- Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep. ePub: 10 September 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7037e1
- Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021. MMWR Morb Mortal Wkly Rep. ePub: 10 September 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7037e2
- O'Brien MP, Forleo-Neto E, Musser BJ, et al. Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021 Aug 4:NEJMoa2109682. doi: 10.1056/NEJMoa2109682. Epub ahead of print. PMID: 34347950; PMCID: PMC8362593.
- McCreary EK, Bariola JR, Minnier T, et al. medRxiv 2021.09.03.21262551; doi: https://doi.org/10.1101/2021.09.03.21262551
Joint Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Associate Medical Director, Infection Prevention and Hospital Epidemiology, University of Pittsburgh School of Medicine
Dr. Martin is a consultant for Infectious Diseases Connect.
Medical Director, Infection Prevention and Hospital Epidemiology, University of Pittsburgh School of Medicine
Dr. Snyder is a consultant for Infectious Diseases Connect.
Director, UPMC Outreach Antimicrobial Stewardship Program, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
The University of Pittsburgh is an affirmative action, equal opportunity institution.